HORIZONROBOT-W
09660
MEITU
01357
SY HOLDINGS
06069
4
XD INC
02400
5
KINGDEE INT'L
00268
HK Stock MarketDetailed Quotes
00570 TRAD CHI MED
- 2.130
- -0.020-0.93%
Market Closed May 16 16:08 CST
10.73BMarket Cap177.50P/E (TTM)
2.150High2.120Low10.97MVolume2.140Open2.150Pre Close23.40MTurnover0.22%Turnover Ratio177.50P/E (Static)5.04BShares4.46052wk High0.47P/B10.73BFloat Cap1.78052wk Low--Dividend TTM5.04BShs Float7.108Historical High--Dividend LFY1.40%Amplitude-0.532Historical Low2.133Avg Price2000Lot Size--Div YieldTTM--Div Yield LFY
TRAD CHI MED News
TRAD CHI MED (00570): Zheng Jun has been appointed as vice president.
TRAD CHI MED (00570) announced that the Board of Directors made a resolution on May 14, 2025, due to reaching the retirement age ...
China Securities Co.,Ltd. is bullish on pharmaceutical companies participating in industry consolidation domestically and actively exploring overseas markets.
Looking ahead to future investment opportunities in the Industry, the bank is Bullish on pharmaceutical companies stabilizing their domestic foundations, actively participating in industry consolidation, managing the rhythm and path externally, and proactively exploring overseas markets.
Same pharmaceuticals, same price? Trump will mandate that USA pharmaceutical prices match those of the lowest-priced countries, stating that "USA pharmaceutical prices could drop by 30% to 80%."
Trump believes that this policy will "unprecedentedly" lower Medical Care costs in the USA, while the export price of American drugs will rise, leading to an increase in Global drug prices "to achieve balance." He stated that he will sign this executive order at 9 a.m. local time on Monday.
AI empowers the FDA! Drug approvals hit the 'fast-forward' button, and a large number of pharmaceutical companies may welcome a 'Gold' period.
The USA Food and Drug Administration (FDA) announced an accelerated plan on Thursday to fully implement AI applications across all subsidiary institutions by June 30, aiming to significantly expedite the approval process for new pharmaceuticals.
Lobbyist groups warn that Trump's drug pricing proposal could lead to a loss of 1 trillion dollars for the pharmaceutical industry.
Lobbying groups warn that USA President Donald Trump's new pharmaceutical pricing proposal could result in losses of up to 1 trillion dollars for pharmaceutical companies over the next decade.
TRAD CHI MED: Annual Report 2024
The trial for importing beef gallbladder has been opened, causing a significant drop in the prices of the most expensive Traditional Chinese Medicine materials.
① The National Medical Products Administration and the General Administration of Customs recently jointly announced a trial for beef bile from specific countries that meet standards for production in Chinese Patent Medicine. ② The price of natural beef bile (gall bile) has dropped from a peak of 1.8 million yuan per kilogram to 1.4 million to -1.45 million yuan per kilogram.
Express News | The Central Committee of the Communist Party of China and the State Council: Explore the establishment of a "white list" system for imported research and development materials for Biomedical enterprises.
Trump Signs Executive Order on Drug Pricing -- WSJ
Caitong: Innovative Drugs and Medical Devices remain an important main line in this round of the bull market in the Medical industry.
The country is likely to accelerate the introduction of policies to encourage expanded domestic demand, which is Bullish for the sectors focused on domestic consumption, including Traditional Chinese Medicine, Medical Services, Internet medicine and pharmacies, medical aesthetics, etc., as an extension of the Health China logic.
Sinolink: Innovative Drugs will be the main growth line in the Pharmaceutical Sector, bringing investment opportunities for left-side sector stocks after the Q1 report.
The reversal of market conditions and improvement in performance after the quarterly report will also bring investment opportunities in individual stocks in sectors such as chain pharmacies, Medical Devices, CXO, generic drugs, Traditional Chinese Medicine, and Medical Services, and it is recommended to increase investment.
Brokerage morning meeting highlights: The short-term bottom of the A-shares has already formed, looking for structural opportunities amid fluctuations.
At today's Brokerage morning meeting, Everbright believes that the market may mainly feature structural trends and hot sector rotations; Sinolink stated that they remain Bullish on the growth potential of Innovative Drugs companies in the Hong Kong and A shares markets; Galaxy Securities indicated that a short-term bottom in A shares has already formed and is seeking structural opportunities amidst the fluctuations.
New Lotus is sprinting towards an IPO, with the second highest market share in the Traditional Chinese Medicine herbal slice Industry, while the gross margin is declining year by year.
Recently, the Global stock market has been experiencing significant turbulence, while the Traditional Chinese Medicine Industry, due to its self-circulation attributes, has been relatively less affected by this round of shocks. At the same time, a Traditional Chinese Medicine decoction company is pushing for an IPO on the Hong Kong stock market. According to Gelonghui's new stock report, on April 3rd, SiChuan Xinhehua Traditional Chinese Medicine Decoction Co., Ltd. (referred to as "Xinhehua") submitted its prospectus to the Hong Kong Stock Exchange, with GF SEC (Hong Kong) and Agricultural Bank of China International serving as joint sponsors. Prior to this, Xinhehua has made several attempts to enter the Capital Markets. In March 2011, Xinhehua submitted a listing application to the GEM of the Shenzhen Stock Exchange; however, considering various factors (including the then Business and
TRAD CHI MED (00570.HK) has received a Shareholding of 50.35 million ordinary shares from China Meheco Group, valued at approximately 93.8524 million Hong Kong dollars.
On April 10, it was reported that, according to documents disclosed by the Hong Kong Stock Exchange on April 10, China Meheco Group Limited increased its Shareholding in TRAD CHI MED (00570.HK) by 50.35 million shares at an average price of HKD 1.864 per share on April 8, valued at approximately HKD 93.8524 million. After the increase, the total number of shares held by China Meheco Group Limited is 1.685 billion shares, raising the shareholding ratio from 32.46% to 33.46%. Image source: Disclosure of interests at the Stock Exchange. What is interest disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more) must disclose their interests.
What is the impact on the domestic Pharmaceutical industry? Many listed companies respond to the USA's tariff on Pharmaceutical.
① Most surveyed listed Pharmaceutical companies are not panicking. Some companies state that if Pharmaceutical tariffs are implemented, they will raise prices to ensure product gross margin; ② Other companies mention that their products are difficult to substitute in the U.S. and are closely monitoring related developments; ③ Industry experts state that if Pharmaceutical tariffs are implemented, compared to Active Pharmaceutical Ingredients and generic drugs, Innovative Drugs may be the least impacted.
China Traditional Chinese Medicine Controlling Shareholder Boosts Stake
China Securities Co.,Ltd.: It is recommended to focus on the new growth and integration opportunities in the Industry.
China Securities Co.,Ltd. remains bullish on high-quality Innovative Drugs companies in 2025 and actively focuses on cutting-edge technologies in pharmaceuticals and medical devices.
Express News | Trump stated that the USA will impose tariffs on pharmaceuticals.
The controlling Shareholder of TRAD CHI MED (00570.HK) increased their Shareholding by 50.35 million shares at an average price of 1.86 yuan.
TRAD CHI MED (00570.HK) announced that on April 8, the controlling Shareholder, China National Pharmaceutical Group, increased its Shareholding in the company by 50.35 million shares at an average price of 1.86 yuan per share. Currently, China National Pharmaceutical Group holds a total of 33.46% of the company's equity.
Express News | TRAD CHI MED: China National Pharmaceutical Group increased its Shareholding by 50.35 million shares.
Market Insights
Deepseek Concept Stocks Deepseek Concept Stocks
DeepSeek is revolutionizing global computing power with groundbreaking AI technology, igniting a new wave of intelligence! Hong Kong technology stocks are expected to benefit. (All third-party logos, brands, or trademarks displayed are for identification purposes only and remain the property of their respective owners.) DeepSeek is revolutionizing global computing power with groundbreaking AI technology, igniting a new wave of intelligence! Hong Kong technology stocks are expected to benefit. (All third-party logos, brands, or trademarks displayed are for identification purposes only and remain the property of their respective owners.)
Unlock Now
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
[2025.2] How should NVIDIA's performance be viewed? The key indicator to watch for short-term stock prices is this.
NVIDIA has been one of the best-performing Technology giants in the US stock market over the past two years, and since 2024, its stock price has experienced sig
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th